ASCO 2023
![Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma](https://pharmtales.com/wp-content/uploads/2023/06/Promising-Early-Antitumor-Activity-of-Camrelizumab-Plus-Famitinib-in-Advanced-Melanoma.jpg)
Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...
![ASCO 2023: Unlocking the Potential of TGF-β Inhibition: GFH018 and Toripalimab Combination Therapy in Immunotherapy-Resistant Patients](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023_-Empowering-Responses-in-Follicular-Lymphoma_-Epcoritamab-Combines-with-Rituximab-and-Lenalidomide-to-Unleash-Promising-Outcomes-2.jpg)
ASCO 2023: Unlocking the Potential of TGF-β Inhibition
ABSTRACT NUMBER: 6026 Recent studies have underscored the crucial role of the TGF-β signalling pathway in shaping the immune microenvironment ...
![ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023_-Empowering-Responses-in-Follicular-Lymphoma_-Epcoritamab-Combines-with-Rituximab-and-Lenalidomide-to-Unleash-Promising-Outcomes.jpg)
ASCO 2023: Empowering Responses in Follicular Lymphoma: Epcoritamab Combines with Rituximab and Lenalidomide to Unleash Promising Outcomes
ABSTRACT NUMBER: 7506 Epcoritamab, a novel bispecific antibody targeting CD3 and CD20, has demonstrated potent T-cell-mediated cytotoxic activity against CD20-positive ...
![ASCO 2023: Unleashing Precision: AFNT-211 Targets KRAS G12V Mutations in Solid Tumours with Potent Efficacy](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023_-Unleashing-Precision_-AFNT-211-Targets-KRAS-G12V-Mutations-in-Solid-Tumours-with-Potent-Efficacy.jpg)
ASCO 2023: Unleashing Precision: AFNT-211 Targets KRAS G12V Mutations in Solid Tumours with Potent Efficacy
ABSTRACT NUMBER: 2543 KRAS mutations are commonly found in various solid tumours and play a significant role in cancer development ...
![ASCO 2023: Game-Changing Results Unveiled: Zanidatamab Shows Promise in HER2-Amplified Biliary Tract Cancers, Revealing a New Hope](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Game-Changing-Results-Unveiled-Zanidatamab-Shows-Promise-in-HER2-Amplified-Biliary-Tract-Cancers-Revealing-a-New-Hope.jpg)
ASCO 2023: Zanidatamab – A New Hope for HER2-Amplified Biliary Tract Cancers
ABSTRACT NUMBER – 4008 A subset of biliary tract cancer cases presents either with overexpression or amplification of the HER2 ...
![ASCO 2023: Elicio Therapeutics Unveils Promising Interim Results from AMPLIFY-201 Phase I Trial of Cutting-Edge Cancer Immunotherapy.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Elicio-Therapeutics-Unveils-Promising-Interim-Results-from-AMPLIFY-201-Phase-I-Trial-of-Cutting-Edge-Cancer-Immunotherapy.jpg)
ASCO 2023: Elicio Therapeutics Unveils Promising Interim Results from AMPLIFY-201 Phase I Trial of Cutting-Edge Cancer Immunotherapy
ABSTRACT NUMBER – 2528 ELI-002 represents a new therapeutic vaccine called AMP that specifically targets KRAS-driven cancers. KRAS mutations are ...
![ASCO 2023: Insights from a Phase III Trial provide information on the intracranial efficacy of Sotorasib compared to Docetaxel in treating KRAS G12C-mutated NSCLC.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Insights-from-a-Phase-III-Trial-provide-information-on-the-intracranial-efficacy-of-Sotorasib-compared-to-Docetaxel-in-treating-KRAS-G12C-mutated-NSCLC.jpg)
Sotorasib vs Docetaxel in KRAS G12C-Mutated NSCLC: ASCO 2023 Highlights
ABSTRACT NUMBER – LBA9016 Amgen has made a courageous endeavor in cancer research over the last four decades by creating ...
![ASCO 2023: MIRASOL's ELAHERE demonstrates transformative potential in treating platinum-resistant ovarian cancer with FRα-positive tumors.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-MIRASOLs-ELAHERE-demonstrates-transformative-potential-in-treating-platinum-resistant-ovarian-cancer-with-FRα-positive-tumors-1.jpg)
ASCO 2023: ELAHERE – A New Hope for Platinum-Resistant Ovarian Cancer Patients
ABSTRACT NUMBER – LBA5507 The MIRASOL trial, presented at ASCO on June 4, demonstrated a significant improvement in the primary ...
![ASCO 2023: Pretreated myeloma patients exhibit a high response rate and manageable toxicity when treated with Linvoseltamab.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Pretreated-myeloma-patients-exhibit-a-high-response-rate-and-manageable-toxicity-when-treated-with-Linvoseltamab.jpg)
ASCO 2023: How Linvoseltamab Can Treat Pretreated Myeloma Patients
ABSTRACT NUMBER – 8006 Linvoseltamab, an investigational bispecific antibody known as BCMAxCD3, shows promising potential in connecting B-cell maturation antigen ...
![ASCO 2023: Patients with HER2-positive mCRC experience anti-tumor effectiveness when administered a reduced dosage of Trastuzumab Deruxtecan.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Patients-with-HER2-positive-mCRC-experience-anti-tumor-effectiveness-when-administered-a-reduced-dosage-of-Trastuzumab-Deruxtecan.jpg)
ASCO 2023: Patients with HER2-Positive MCRC Benefit from Lower Dose of Trastuzumab Deruxtecan
ABSTRACT NUMBER – 3501 The Phase II DESTINY-CRC02 study, presented at the 2023 ASCO Annual Meeting, reported that administering ENHERTU ...
![ASCO 2023: Promising Results from Phase I Study of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations in Solid Tumors](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023Promising-Results-from-Phase-I-Study-of-Sleeping-Beauty-TCR-T-Cells-Targeting-Shared-KRAS-and-TP53-Mutations-in-Solid-Tumors.jpg)
ASCO 2023: Promising Results from Sleeping Beauty TCR-T Cells
ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...
![ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023Kelun-Pharmas-SKB264-shows-early-signs-of-potential-in-NSCLC-patients.jpg)
ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients
ABSTRACT NUMBER – 9114 SKB264 is an innovative anti-TROP2 ADC that specifically targets a poor prognosis marker found in 70% ...
![EpicentRx Provides Latest Updates on Oncology Clinical Development Programs at 2023 ASCO Annual Meeting](https://pharmtales.com/wp-content/uploads/2023/06/EpicentRx-Provides-Latest-Updates-on-Oncology-Clinical-Development-Programs-at-2023-ASCO-Annual-Meeting.jpg)
EpicentRx Provides Latest Updates on Oncology Clinical Development Programs at 2023 ASCO Annual Meeting
During the 2023 American Society of Clinical Oncology (ASCO) meeting, EpicentRx, Inc., a clinical-stage biopharmaceutical company, provided updates on the ...
![ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-BREYANZI-Shines-as-First-CAR-T-Therapy-with-Deep-and-Lasting-Impact-in-Chronic-Lymphocytic-Leukemia.jpg)
ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia
The initial findings from the important TRANSCEND CLL 004 study, which is evaluating the use of BREYANZI (lisocabtagene maraleucel) in ...